| Citation: |
LIU Jia, JIA Yujing, WANG Huijuan, GAO Shuqing. Efficacy of montelukast combined with erythromycin in the treatment of children with Mycoplasma pneumoniae infection[J]. Journal of Clinical Medicine in Practice, 2023, 27(7): 129-132, 148. DOI: 10.7619/jcmp.20222245
|
To observe the clinical efficacy of montelukast combined with erythromycin in the treatment of children with Mycoplasma pneumoniae infection and its effect on pulmonary function and serum stress indexes.
A total of 94 children with Mycoplasma pneumoniae were selected as study objects, and were randomly divided into observation group and control group, with 47 cases in each group. The control group was given conventional drug treatment and erythromycin treatment; the observation group was given combined treatment with montelukast sodium chewable tablet based on the control group. The clinical efficacy after treatment, the disappear time of clinical symptoms, and the occurrence of adverse reactions of the two groups were observed. The changes of pulmonary function indexes[forced expiratory volume in the first second (FEV1), peak expiratory flow (PEF), forced vital capacity (FVC)], serum stress indexes[tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), C-reactive protein (CRP)] before and after treatment in the two groups were observed.
The total effective rate in the observation group was higher than that of the control group (97.87% versus 89.36%, P>0.05). The total remarked rate of the observation group was higher than that of control group, and the difference was statistically significant (76.60% versus 55.32%, P < 0.05). The disappearance time of fever, cough and lung rale in the observation group was (3.21±0.75) d, (6.77±1.52) d and (4.57±1.19) d, which were shorter than (3.68±0.81) d, (8.02±1.88) d and (5.38±1.36) d, respectively in the control group (P < 0.05). After treatment, the levels of FEV1, PEF and FVC in two groups were higher than before treatment, and their levels in the observation group were higher than control group (P < 0.05). After treatment, the levels of TNF-α, IL-6 and CRP in two groups were lower than before treatment, and their levels in the observation group were lower than those in the control group (P < 0.05). The adverse reaction rate in the observation group was slightly lower than that in the control group, but no significant differences were observed (12.77% versus 17.02%, P>0.05).
Montelukast combined with erythromycin in the treatment of children with Mycoplasma pneumoniae infection has better clinical efficacy than erythromycin alone, and can significantly shorten the disappearance time of fever, cough and other symptoms in children, and significantly improve the level of lung function indexes and serum stress indexes in the body.
| [1] |
陈芸, 韩长青, 赵凤兰, 等. 连花清瘟颗粒联合阿奇霉素治疗小儿肺炎支原体肺炎的临床观察[J]. 世界中医药, 2020, 15(1): 76-80. doi: 10.3969/j.issn.1673-7202.2020.01.014
|
| [2] |
PENG Y Y, CHEN Z, LI Y J, et al. Combined therapy of Xiaoer Feire Kechuan oral liquid and azithromycin for Mycoplasma pneumoniae pneumonia in children: a systematic review & meta-analysis[J]. Phytomedicine, 2022, 96: 153899. doi: 10.1016/j.phymed.2021.153899
|
| [3] |
ZHANG M Y, ZHAO Y, LIU J F, et al. Efficacy of different antibiotics in treatment of children with respiratory Mycoplasma infection[J]. World J Clin Cases, 2021, 9(23): 6717-6724. doi: 10.12998/wjcc.v9.i23.6717
|
| [4] |
韩丽芳. 玉屏风颗粒联合阿奇霉素治疗小儿支原体肺炎的临床观察[J]. 中国民间疗法, 2020, 28(10): 70-71. doi: 10.19621/j.cnki.11-3555/r.2020.1032
|
| [5] |
潘晓明, 姚小飞, 陈磊, 等. 小儿热速清颗粒治疗小儿肺炎支原体肺炎的临床效果[J]. 世界中医药, 2021, 16(9): 1454-1458. doi: 10.3969/j.issn.1673-7202.2021.09.019
|
| [6] |
崔珍, 金晓群, 李永莲, 等. 孟鲁司特治疗肺炎支原体肺炎伴喘息患儿临床评价[J]. 中国药业, 2018, 27(8): 49-51. doi: 10.3969/j.issn.1006-4931.2018.08.016
|
| [7] |
WU H T, DING X, ZHAO D Y, et al. Effect of montelukast combined with methylprednisolone for the treatment of Mycoplasma pneumonia[J]. J Int Med Res, 2019, 47(6): 2555-2561. doi: 10.1177/0300060518820412
|
| [8] |
中华医学会儿科学分会呼吸学组, 《中华实用儿科临床杂志》编辑委员会. 儿童肺炎支原体肺炎诊治专家共识(2015年版)[J]. 中华实用儿科临床杂志, 2015, 30(17): 1304-1308. doi: 10.3760/cma.j.issn.2095-428X.2015.17.006
|
| [9] |
张军, 封其华. 参附注射液联合阿奇霉素治疗小儿支原体肺炎的临床疗效及机制[J]. 西安交通大学学报: 医学版, 2019, 40(6): 1012-1017. https://www.cnki.com.cn/Article/CJFDTOTAL-XAYX201906035.htm
|
| [10] |
殷剑松, 徐迪, 薛菲, 等. 儿童肺炎支原体肺炎与血脂水平的相关性研究[J]. 实用临床医药杂志, 2022, 26(5): 105-108, 112. doi: 10.7619/jcmp.20213995
|
| [11] |
熊学敏, 邵荣昌, 彭瑞, 等. 大剂量维生素C联合罗红霉素对小儿肺炎支原体肺炎的疗效[J]. 西北药学杂志, 2020, 35(1): 121-125. doi: 10.3969/j.issn.1004-2407.2020.01.028
|
| [12] |
ZHOU H, CHEN X J, LI J. Effect of methylprednisolone plus azithromycin on fractional exhaled nitric oxide and peripheral blood eosinophils in children with refractory Mycoplasma pneumoniae pneumonia[J]. J Coll Physicians Surg Pak, 2022, 32(1): 33-36. doi: 10.29271/jcpsp.2022.01.33
|
| [13] |
冯伟伟, 阮为勇, 王宇军, 等. 苏黄止咳胶囊与孟鲁司特治疗小儿肺炎支原体感染后咳嗽的疗效观察[J]. 现代中西医结合杂志, 2015, 24(29): 3239-3241. doi: 10.3969/j.issn.1008-8849.2015.29.017
|
| [14] |
WU S H, CHEN X Q, KONG X, et al. Characteristics of respiratory syncytial virus-induced bronchiolitis co-infection with Mycoplasma pneumoniae and add-on therapy with montelukast[J]. World J Pediatr, 2016, 12(1): 88-95. doi: 10.1007/s12519-015-0024-4
|
| [15] |
张益民, 曹阳, 郭桂梅. 孟鲁司特钠片联合硫酸特布他林雾化治疗小儿肺炎支原体感染并咳嗽变异性哮喘82例疗效观察[J]. 中国药业, 2018, 27(13): 59-61. doi: 10.3969/j.issn.1006-4931.2018.13.019
|
| [16] |
方瑞, 汪燕, 项云, 等. 孟鲁司特联合阿奇霉素对小儿上呼吸道肺炎支原体感染的疗效观察[J]. 实用临床医药杂志, 2018, 22(17): 104-107. doi: 10.7619/jcmp.201817031
|
| [17] |
李长江. 布地奈德雾化吸入治疗小儿支原体肺炎的疗效及胸部CT表现变化观察[J]. 中国CT和MRI杂志, 2021, 19(4): 54-56, 116. https://www.cnki.com.cn/Article/CJFDTOTAL-CTMR202104018.htm
|
| [18] |
成锦荣. 阿奇霉素联合孟鲁司特钠治疗小儿支原体肺炎疗效观察[J]. 中国药物与临床, 2020, 20(23): 3975-3977. https://www.cnki.com.cn/Article/CJFDTOTAL-YWLC202023044.htm
|
| 1. |
汤思，陈学杰. 直接抗人球蛋白试验阳性分型与输血疗效的相关性. 吉林医学. 2024(02): 295-297 .
| |
| 2. |
杨占甲，李丽娟，宋银森. 多发性骨髓瘤患者红细胞输注效果的影响因素探讨. 中国实用医刊. 2024(13): 66-69 .
| |
| 3. |
梁冬香，钟昌瑞，傅春花，邱启东. 直接抗人球蛋白试验凝集强度的结果分析及临床意义. 临床血液学杂志. 2024(12): 905-908 .
| |
| 4. |
闻才李，张慧，杨吉岳，孙一心，程晓文. 直接抗人球蛋白试验阳性患者298例的病因回顾性分析. 医药论坛杂志. 2022(08): 72-74+78 .
| |
| 5. |
胡泽斌，孙彬裕，孙晶，王布强，于婷. 抗人球蛋白检测卡行业标准的研究. 中国医药生物技术. 2022(05): 449-452 .
|
© 2020 《实用临床医药杂志》编辑部
Address: 江苏省扬州市江阳中路136号，扬州大学江阳路北校区14号楼201室China Pos: 225009Tel: 0514-87978917、87978989、87978807
Supported by:
Beijing Renhe Information Technology Co., Ltd.
苏公网安备 32100302010246号
DownLoad: